AI Visualize v. Nuance: Federal Circuit Affirms Dismissal in Medical Imaging Patent Dispute

🔍 Run FTO analysis 🔎 Search patents

Case Overview

The Parties

⚖️ Plaintiff

A patent holder asserting intellectual property rights related to advanced web-based visualization platforms for medical imaging. The company’s IP portfolio targets the intersection of cloud-based access and diagnostic imaging.

🛡️ Defendants

Nuance, a Microsoft subsidiary, is a major player in AI-powered healthcare technology. Mach7 is a medical imaging IT company specializing in enterprise imaging platforms. Both offer radiology workflow solutions.

The Patents at Issue

Four U.S. patents were asserted by AI Visualize, collectively covering methods and systems enabling fast access to advanced visualization of medical scans through a dedicated web portal. This technology area is of growing commercial significance in healthcare IT.

  • US8701167B2 — Web-based visualization systems for medical scan data
  • US9106609B2 — Systems for browser-based diagnostic imaging without local software
  • US9438667B2 — Methods for fast access to advanced visualization of medical scans via web portal
  • US10930397B2 — Infrastructure for cloud-based access and diagnostic imaging
🔍

Developing health IT solutions?

Check if your web-based medical imaging solution might infringe similar patents before launch.

Run FTO Check →

The Verdict & Legal Analysis

Outcome

The Federal Circuit **affirmed** the lower court’s ruling, and the appeal was **dismissed**, closing the case as of April 4, 2024. No specific damages award or injunctive relief was identified in the case record, which is consistent with a dismissal outcome rather than a merits adjudication on infringement liability.

Key Legal Issues

The affirmance of dismissal — rather than a finding of non-infringement after full trial — suggests the case may have been resolved at a pretrial procedural threshold. In Federal Circuit patent appeals, dismissals frequently arise from claim construction rulings, subject matter eligibility challenges under 35 U.S.C. § 101 (particularly prevalent for software-implemented and web-based medical systems), or standing/pleading deficiencies.

Given the technology at issue — web portal-based access to medical visualization — § 101 eligibility challenges are a credible procedural basis for early dismissal. Federal courts have scrutinized software patents in healthcare IT under the *Alice Corp. v. CLS Bank International* framework, and patents directed at “fast access” via web portals can be characterized as abstract ideas absent sufficiently inventive technical implementation.

This affirmance carries meaningful precedential weight for **web-based medical imaging patents**, a category that straddles software patent eligibility doctrine and healthcare IT claim drafting practice. It reinforces the difficulty of sustaining broad software-implemented claims at the appellate level in the Federal Circuit, particularly where accused products involve established web delivery architectures.

⚠️

Freedom to Operate (FTO) Analysis

This case highlights critical IP risks in medical imaging and health informatics. Choose your next step:

📋 Understand This Case’s Impact

Learn about the specific risks and implications from this medical imaging patent litigation.

  • Identify vulnerabilities in web-based medical imaging patents
  • Analyze defense strategies against software-implemented claims
  • Review the Federal Circuit’s approach to § 101 challenges
📊 View Patent Landscape
⚠️
High Risk Area

Web portal-based medical imaging patents

📋
4 Patents at Issue

Software-implemented visualization claims

§ 101 Eligibility

Key defense for abstract ideas

✅ Key Takeaways

For Patent Attorneys & Litigators

Federal Circuit affirmance of dismissal in a multi-patent infringement action reinforces procedural defense strategies as cost-effective tools.

Search related case law →

Web-based method patents in healthcare IT remain vulnerable to § 101 challenges; claim drafting must anticipate this.

Explore precedents →

Four-patent assertion portfolios require coordinated claim construction strategies — weakness in one patent can undermine the entire assertion.

Analyze claim construction trends →
🔒
Unlock Strategic R&D & IP Insights
Get actionable guidance on proactive FTO, technical differentiation, and monitoring patent scope for medical imaging and software-implemented healthcare innovations.
Proactive FTO Guidance Technical Differentiation Tips Software Patent Eligibility
Explore Full Analysis in PatSnap Eureka

Frequently Asked Questions

Ready to Strengthen Your Patent Strategy?

Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.

PatSnap IP Intelligence Team

Patent Research & Competitive Intelligence · PatSnap

This analysis was produced by the PatSnap IP Intelligence Team — a group of patent analysts, IP strategists, and data scientists who work daily with PatSnap’s global patent database of over 2 billion structured data points across patents, litigation records, scientific literature, and regulatory filings.

The team specialises in tracking landmark litigation outcomes, translating complex court rulings into actionable IP strategy, and identifying the competitive intelligence implications for R&D and legal teams. All case analysis is grounded in primary sources: official court records, USPTO filings, and Federal Circuit opinions.

📊 2B+ Patent Data Points 🌍 120+ Countries Covered 🏢 18,000+ Customers Worldwide ⚖️ Global Litigation Database 🔍 Primary Source Verified

References

  1. United States Court of Appeals for the Federal Circuit — Case No. 22-2109
  2. USPTO Patent Center
  3. PACER (Public Access to Court Electronic Records)
  4. Cornell Legal Information Institute — 35 U.S.C. § 101
  5. PatSnap — IP Intelligence Solutions for Law Firms

This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.

⚖️ Disclaimer: This article is for informational purposes only and does not constitute legal advice. The analysis presented reflects publicly available case information and general legal principles. For specific advice regarding patent litigation, FTO analysis, or IP strategy, please consult a qualified patent attorney.